Company intelligence / Profile preview

BioOra

Christchurch, Canterbury, New Zealand

Ownership: Private
Development stage: Other

Overview

BioOra is commercializing a third generation CAR-T cell therapy for non-Hodgkin lymphoma (NHL); Phase 1 completed in 2024, with Phase 2 underway in New Zealand across three sites for 60 patients, demonstrating improved safety compared to prior generations and aiming to expand patient access through automated, local GMP manufacturing

Therapeutic areas: OncologyHematology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

atlacabtagene autoleucel

Partnerships

The Malaghan Institute of Medical Research (clinical/scientific partnership)Wellington Zhaotai Therapies (clinical trial)Callaghan Innovation (government technology incubator)

Beyond the preview

Go deeper on BioOra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioOra.

Explore the full profile